Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...

Aging is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a ...

The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...

Karan Arora, senior vice president of advanced assays, AI, and pharma services at Leica Biosystems outlines the critical role ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial ...